PBYI

6.89

0.14% -0.01

Handel nachbörslich: 6.80 -0.09 -1.31%

Puma Biotechnology Inc (PBYI)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$6.90

Offen:

$6.92

24-Stunden-Volumen:

346.42K

Relative Volume:

0.86

Marktkapitalisierung:

$350.54M

Einnahmen:

$228.37M

Nettoeinkommen (Verlust:

$31.11M

KGV:

11.28

EPS:

0.6108

Netto-Cashflow:

$41.73M

1W Leistung:

+12.40%

1M Leistung:

+13.88%

6M Leistung:

+36.98%

1J Leistung:

+137.59%

1-Tages-Spanne:

$6.70

$7.02

1-Wochen-Bereich:

$6.15

$7.02

52-Wochen-Spanne:

$2.575

$7.68

Puma Biotechnology Inc Stock (PBYI) Company Profile

Firmenname

Puma Biotechnology Inc

Sektor

Healthcare (1116)

Branche

Biotechnology (624)

Telefon

(424) 248-6500

Adresse

10880 WILSHIRE BLVD., LOS ANGELES, CA

Mitarbeiter

179

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PBYI's Discussions on Twitter

Compare PBYI vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PBYI Puma Biotechnology Inc	6.89	351.05M	228.37M	31.11M	41.73M	0.6108
VRTX Vertex Pharmaceuticals Inc	434.30	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	763.04	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.25	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.34	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.81	35.01B	606.42M	-1.28B	-997.58M	-6.403

Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-09-28	Hochstufung	Citigroup	Neutral → Buy
2020-06-25	Fortgesetzt	BofA/Merrill	Underperform
2019-10-08	Herabstufung	Goldman	Neutral → Sell
2019-05-10	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2019-05-10	Herabstufung	Citigroup	Buy → Neutral
2019-01-17	Eingeleitet	Leerink Partners	Mkt Perform
2019-01-03	Herabstufung	Guggenheim	Buy → Neutral
2018-11-19	Hochstufung	Goldman	Sell → Neutral
2018-11-02	Herabstufung	BofA/Merrill	Buy → Underperform
2018-11-02	Herabstufung	JP Morgan	Neutral → Underweight
2018-10-01	Eingeleitet	Cantor Fitzgerald	Overweight
2018-09-17	Eingeleitet	Goldman	Sell
2018-05-11	Bestätigt	Stifel	Buy
2017-11-10	Bestätigt	Citigroup	Buy
2017-11-10	Bestätigt	RBC Capital Mkts	Sector Perform
2017-10-02	Bestätigt	Stifel	Buy
2017-09-11	Bestätigt	Credit Suisse	Outperform
2017-07-10	Fortgesetzt	Leerink Partners	Outperform
2017-06-06	Bestätigt	RBC Capital Mkts	Sector Perform
2017-05-25	Bestätigt	RBC Capital Mkts	Sector Perform
2017-03-02	Bestätigt	RBC Capital Mkts	Sector Perform

Alle ansehen

Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten

Apr 04, 2026

Investor Mood: Is Puma Biotechnology Inc undervalued by DCF analysisWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn

Apr 04, 2026

Apr 03, 2026

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 - BioSpace

Apr 03, 2026

Apr 02, 2026

Puma Biotechnology reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Apr 02, 2026

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Apr 02, 2026

Apr 01, 2026

Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com

Apr 01, 2026

Pharma News: Is Puma Biotechnology Inc a momentum stockAnalyst Downgrade & Capital Efficiency Focused Ideas - baoquankhu1.vn

Apr 01, 2026

Mar 31, 2026

Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat

Mar 31, 2026

PBYI SEC FilingsPuma Biotechnology Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 31, 2026

Mar 28, 2026

Recap Report: What is Puma Biotechnology Incs 5 year growth outlook2026 Technicals & Low Risk Growth Stock Ideas - baoquankhu1.vn

Mar 28, 2026

Mar 27, 2026

Puma Biotechnology Q4 2025 slides: NERLYNX revenue rises 15% sequentially - Investing.com

Mar 27, 2026

Earnings call transcript: Puma Biotechnology Inc. reports strong Q4 2025 results - in.investing.com

Mar 27, 2026

Vanguard disaggregates holdings; Puma Biotechnology (PBYI) shows 0 shares reported - stocktitan.net

Mar 27, 2026

Mar 25, 2026

Forecast Cut: Is Puma Biotechnology Inc a momentum stockPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn

Mar 25, 2026

Rate Hike: Can Puma Biotechnology Inc be the next market leaderPortfolio Update Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Mar 25, 2026

Mar 24, 2026

Puma Biotechnology stock declines more than 9% in a month: Here's why - msn.com

Mar 24, 2026

Mar 21, 2026

Wall Street Zen Upgrades Puma Biotechnology (NASDAQ:PBYI) to Strong-Buy - MarketBeat

Mar 21, 2026

Mar 19, 2026

Shorts Report: Is Puma Biotechnology Inc undervalued by DCF analysis2026 Trading Volume Trends & Reliable Price Breakout Signals - baoquankhu1.vn

Mar 19, 2026

Mar 18, 2026

Whats the MACD signal for Puma Biotechnology Inc2026 Market WrapUp & Weekly Setup with ROI Potential - baoquankhu1.vn

Mar 18, 2026

Earnings Miss: Can Puma Biotechnology Inc be the next market leaderQuarterly Trade Summary & Expert Verified Movement Alerts - baoquankhu1.vn

Mar 18, 2026

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why - Yahoo Finance

Mar 18, 2026

Buy Signal: Is Puma Biotechnology Inc trading at a discount2026 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Puma Biotechnology Stock Crosses 200-Day Moving Average - National Today

Mar 17, 2026

Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat

Mar 17, 2026

Mar 12, 2026